Blog | HemaCare

CD34+ Stem Cells Used to Study Carbon Nanoparticle Absorption

Jan 21, 2020 10:05:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Drug Discovery, Stem Cells


Researchers studied the potential harm of carbon nanoparticle absorption but found that lysosome encapsulation may prevent cell-damage from occurring.  

Carbon nanoparticles are very promising tools for use in the delivery of therapeutic agents in the body and for bioimaging applications to monitor drug distribution and efficacy. These particles have been successfully attached to various therapeutic agents including small drug molecules, vaccines, immunotherapeutic agents, and gene therapies. Agents can be delivered directly into cell targets without first being metabolized. However, are there adverse effects that could potentially overshadow these benefits?

Read More

Could Cell Therapy Boost Cardiac Function in DMD Patients?

Jan 14, 2020 10:06:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Bone Marrow, Cell Therapy, Stem Cells


Mesenchymal Stem cells (MSCs) derived from mouse muscle tissue and bone marrow were used in an experimental cell therapy for Duchenne Muscular Dystrophy.

Duchenne muscular dystrophy (DMD) is an incurable, progressively debilitating muscular-skeletal and cardiac disease caused by a mutation in the dystrophin gene. The encoded dystrophin protein is part of a larger protein complex involved in anchoring the muscle cytoskeleton to components of the extracellular matrix. Loss of dystrophin leads to muscle wasting, and heart disease is a major cause of death in patients with DMD. Therefore, the availability of effective treatments to address cardiac function in people with DMD is vital.

Read More

HemaCare Publication Highlights Role of Cell Therapy Starting Materials

Jan 7, 2020 10:04:00 AM / by Nancy Andon, MSc posted in Gene Therapy, Cell Therapy


HemaCare Corporation’s latest publication in BioPharm International [1] sheds light on a topic that has been preoccupying some of the best minds in cell therapy research; the need to ensure a reliable supply of top-notch starting materials for up-and-coming cell and gene therapies.

Unlike traditional medical treatments, the raw materials for these therapies cannot simply be manufactured. Instead, the supply of starting materials relies on a steady influx of voluntary donors willing to take the time to undertake a fairly complex screening process and donate peripheral blood or bone marrow for altruistic reasons. Nor is a reliable donor pool the only criteria necessary to supplying materials for a successful cellular therapeutic. Starting material quality and consistency ultimately determine the reliable efficacy of the final product.

Read More

Nanotechnology for Acute Kidney Injury

Dec 30, 2019 10:06:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cell Therapy, Drug Discovery


While there is no cure for acute kidney injury, a research team out of the University of Wisconsin-Madison may be shedding some new light on this condition.

Acute kidney injury (AKI) is characterized by a sudden decline in kidney function. This decline is marked by a significant rise in serum creatinine levels that may be accompanied by a reduction in urine output. Some cases of AKI require kidney transplantation or can lead to death. There are a number of causes of AKI, including injury from gadolinium-based contrast agents (nephrogenic systemic fibrosis), rhabdomyolysis, low blood volume, and vasculitis.

Read More

Tests in New Immunotherapy Targets Macrophages Instead of Cancer Cells

Dec 23, 2019 10:07:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, Macrophages, Immunotherapy (Immunology)


A collaborative team of scientists from Denmark, France, the UK, and the US recognized the potential to target CD163 macrophages for a novel approach to cancer immunotherapy.

Macrophages are one of many types of immune system cells of the body, and they function to phagocytize and digest invading substances including bacteria and other microorganisms; they also digest cellular debris and cancer cells. However, there are a subset of macrophages (CD163 macrophages) that actually supports tumor survival and impedes T-cell attack of tumors. Expression of CD163 by these macrophages is associated with a poorer prognosis for a number of human cancers, such as malignant melanoma.

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts